Arcus Biosciences Inc
RCUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.55B
Close$
$-24.24
201.6% downside
Current Fair Value
201.6% downsideOvervalued by 201.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.55 Billion |
|---|---|
| Enterprise Value | $2.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.87 |
| Outstanding Shares | 125,400,000 |
Return
| Return on Equity | -68.89% |
|---|---|
| Return on Assets | -36.21% |
| Return on Invested Capital | -45.69% |
Valuation & Multiples
| P/E Ratio | -8.61 |
|---|---|
| PEG | -60.28 |
| Price to Sales | 23.86 |
| Price to Book Ratio | 5.97 |
| Enterprise Value to Revenue | 10.53 |
| Enterprise Value to EBIT | -6.9 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.95
Average shareholder expectationRevenue Estimate
$24.38 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$25.05 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4612▲ 40.33% |
|---|---|
| Total Calls | 347,800▼ 90.53% |
| Total Puts | 160,400▼ 24.59% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.87%▼ 3.14% |
|---|---|
| Total Invested | $2.57B▼ 11.09% |
| Investors Holding | 221▼ 3.00% |
ESG Score
No data